Check out our most popular compounded medications! Get Started
Cevimeline HCl 30 mg/10 mL Oral Solution is a liquid formulation designed for oral administration, where the active ingredient, Cevimeline Hydrochloride, is dissolved in a suitable solvent. This solution provides accurate dosing and convenient delivery, making it ideal for patients requiring specific dosage strengths or those who have difficulty swallowing tablets or capsules.
This formulation is primarily used to treat symptoms associated with Sjögren's syndrome, a condition characterized by dry mouth and dry eyes due to reduced saliva and tear production. By stimulating the secretion of saliva and tears, Cevimeline HCl helps alleviate these symptoms, improving the quality of life for individuals affected by this autoimmune disorder.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Cevimeline Hydrochloride 30 mg/10 mL Oral Solution is a compounded liquid medication formulated to provide relief from symptoms associated with dry mouth, particularly in patients diagnosed with Sjögren's Syndrome. This formulation offers precise dosing and ease of administration, especially for those who may have difficulty swallowing tablets or require a specific dosage strength not commercially available.
Cevimeline is a cholinergic agonist that selectively binds to muscarinic receptors, stimulating exocrine gland secretion, including salivary and sweat glands. By enhancing salivary flow, it helps alleviate the discomfort of dry mouth (xerostomia), thereby improving oral health
Cevimeline HCl is a muscarinic agonist primarily used to treat symptoms of dry mouth in patients with Sjögren's syndrome. It works by stimulating the secretion of saliva, thereby alleviating the discomfort associated with dry mouth. When considering the use of Cevimeline HCl 30 mg/10 mL Oral Solution, it is crucial to be aware of potential drug interactions that may affect the efficacy and safety of the treatment.
Patients and prescribers should be aware that Cevimeline may interact with other medications that have anticholinergic properties. These include certain antihistamines, antipsychotics, and medications used to treat overactive bladder, as they may counteract the effects of Cevimeline by inhibiting its action on muscarinic receptors. This could potentially reduce the effectiveness of Cevimeline in stimulating saliva production.
Additionally, Cevimeline may interact with beta-blockers, which are commonly prescribed for hypertension and other cardiovascular conditions. The combination of Cevimeline and beta-blockers may lead to an enhanced risk of bradycardia (slow heart rate) due to their combined effects on the heart. Patients should be monitored for signs of bradycardia, and dose adjustments may be necessary.
Another important consideration is the interaction between Cevimeline and medications that affect the cytochrome P450 enzyme system, particularly CYP2D6 and CYP3A4. Drugs that inhibit these enzymes, such as certain antifungals (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), may increase the plasma concentration of Cevimeline, potentially leading to an increased risk of side effects. Conversely, inducers of these enzymes, such as rifampin, may decrease the effectiveness of Cevimeline by reducing its plasma levels.
Patients taking medications for asthma or chronic obstructive pulmonary disease (COPD) should also exercise caution, as Cevimeline may exacerbate bronchoconstriction due to its muscarinic agonist activity. It is advisable to monitor respiratory function closely and adjust treatment as necessary.
For patients with a history of cardiovascular disease, including arrhythmias, the use of Cevimeline should be approached with caution. The drug's potential to affect heart rate and rhythm necessitates careful monitoring and possibly an alternative treatment strategy if adverse cardiac effects are observed.
As with any medication, it is essential for patients to inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and supplements, to ensure a comprehensive evaluation of potential drug interactions. Prescribers should conduct a thorough medication review and consider any necessary adjustments to the patient's treatment regimen to optimize therapeutic outcomes while minimizing risks.
If you have any questions or require further information regarding the use of Cevimeline HCl 30 mg/10 mL Oral Solution and its potential drug interactions, please reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to assist you.
Cevimeline HCl 30 mg/10 mL Oral Solution is a specially compounded liquid formulation designed to deliver precise dosing of the active ingredient, Cevimeline Hydrochloride, in a convenient oral solution. This formulation is particularly beneficial for patients who require a specific dosage strength that may not be available in commercially manufactured products or for those who have difficulty swallowing tablets or capsules. The liquid form allows for easy administration and absorption, ensuring that patients receive the intended therapeutic effects of the medication.
Cevimeline is a cholinergic agonist that primarily acts on muscarinic receptors, specifically the M3 receptors, which are predominantly found in exocrine glands such as the salivary and sweat glands. By stimulating these receptors, Cevimeline increases the secretion of saliva and sweat, which can be particularly beneficial in treating conditions such as Sjögren's syndrome, where patients suffer from dry mouth (xerostomia) due to reduced saliva production. This increase in salivary flow helps alleviate the discomfort associated with dry mouth, improving oral health and enhancing the quality of life for patients.
The oral solution form of Cevimeline HCl ensures that the medication is rapidly absorbed into the bloodstream, providing prompt relief from symptoms. The liquid formulation also allows for flexible dosing, which can be easily adjusted by healthcare providers to meet the specific needs of each patient. This is especially important in managing chronic conditions where the severity of symptoms may vary over time, requiring tailored dosing regimens to achieve optimal therapeutic outcomes.
For prescribers, the compounded Cevimeline HCl 30 mg/10 mL Oral Solution offers a customizable option to address the unique needs of patients who may not respond adequately to standard treatments or who require a different dosage form. The ability to adjust the concentration and volume of the solution provides a level of precision in dosing that is not always possible with commercially available products. This flexibility can lead to improved patient adherence and satisfaction, as the medication can be tailored to fit seamlessly into their daily routine.
Patients using Cevimeline HCl 30 mg/10 mL Oral Solution should follow their healthcare provider's instructions carefully to ensure the best possible outcomes. It is important to measure the dose accurately using a suitable measuring device, such as an oral syringe or dosing cup, to avoid under or overdosing. Patients should also be aware of potential side effects, such as increased sweating, nausea, or headache, and report any adverse reactions to their healthcare provider promptly.
If you have any questions about Cevimeline HCl 30 mg/10 mL Oral Solution or how it may benefit you or your patients, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to provide guidance and support to ensure the safe and appropriate use of this medication.
Cevimeline HCl 30 mg/10 mL Oral Solution is primarily used to treat symptoms of dry mouth in patients with Sjögren's syndrome by stimulating saliva production.
This oral solution should be taken by mouth, using a measuring device to ensure accurate dosing. Follow your healthcare provider's instructions regarding the dosage and frequency.
Yes, Cevimeline HCl Oral Solution can be taken with or without food. However, taking it with food may help reduce any potential stomach upset.
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not double the dose to catch up.
Common side effects may include sweating, nausea, runny nose, and increased urination. If you experience severe side effects or signs of an allergic reaction, contact your healthcare provider immediately.
Store the oral solution at room temperature, away from light and moisture. Keep it out of reach of children and pets.
Cevimeline may cause dizziness or blurred vision. Avoid driving or operating heavy machinery until you know how the medication affects you.
If you are pregnant or breastfeeding, consult your healthcare provider before using Cevimeline HCl Oral Solution to discuss potential risks and benefits.
Yes, Cevimeline can interact with other medications. Inform your healthcare provider about all the medications and supplements you are taking to avoid potential interactions.
In case of an overdose, seek immediate medical attention or contact a poison control center. Symptoms of overdose may include severe dizziness, confusion, or difficulty breathing.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
